Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
SunTrust Robinson Humphrey Downgrades Juno Therapeutics (JUNO) to Hold
November 25, 2016 6:48 AM ESTSunTrust Robinson Humphrey downgraded Juno Therapeutics (NASDAQ: JUNO) from Buy to Hold with a price target of $25.00 (from $48.00) after the ROCKET study evaluating JCAR015 in no-option Adult ALL was placed on clinical hold for the second time.
The analyst sees reduced visibility and increased... More
Juno Therapeutics (JUNO) PT Lowered to $34 at Maxim Group
November 23, 2016 1:51 PM ESTMaxim Group analyst Jason McCarthy lowered his price target on Juno Therapeutics (NASDAQ: JUNO) to $34.00 (from $50.00) after the ROCKET study evaluating JCAR015 in no-option Adult ALL (Acute Lymphoblastic Leukemia) was placed on clinical hold for the second time. The firm maintained a Buy rating.
McCarthy highlighted:
The ROCKET study evaluating JCAR015 in no-option Adult ALL (Acute Lymphoblastic Leukemia) was placed on clinical hold for the second time. Two more patients died due to treatment-related neurotoxicity (cerebral edema), the same cause of death observed in July when ROCKET was... MoreJuno Therapeutics (JUNO) CEO Bishop: Second JCAR015 Patient with Brain Swelling has Died - Conf. call
November 23, 2016 8:44 AM ESTJuno Therapeutics (NASDAQ: JUNO) CEO Hans Bishop said that the second JCAR015 patient with brain swelling has died, according to the company's conference call on Wednesday. Patients who died were treated last week, the CEO noted.
The company has treated 12 patients since... More
Juno Therapeutics (JUNO) Sinks 40% as Trading Resumes after Clinical Hold
November 23, 2016 8:33 AM ESTJuno Therapeutics (NASDAQ: JUNO) resumed trading down 40% after the company announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the ROCKET trial. The clinical... More
Juno Therapeutics (JUNO) to Resume Trading at 8:30AM ET after Clinical Hold Announced
November 23, 2016 8:05 AM ESTJuno Therapeutics (NASDAQ: JUNO) set to resume trading at 8:30AM ET after it voluntarily placed on hold the Phase II clinical trial of JCAR015
... MoreJuno Therapeutics (JUNO) Halted for News Release
November 23, 2016 8:01 AM ESTJuno Therapeutics (NASDAQ: JUNO) Halted for News Release
... More